Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Soluble CD44v6 is Not a Sensitive Tumor Marker in Patients with Head and Neck Squamous Cell Cancer

MICHAELA ANDRATSCHKE, SARITA CHAUBAL, CHRISTOF PAULI, BRIGITTE MACK, HJALMAR HAGEDORN and BARBARA WOLLENBERG
Anticancer Research July 2005, 25 (4) 2821-2826;
MICHAELA ANDRATSCHKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Michaela.Andratschke@med.uni-muenchen.de
SARITA CHAUBAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTOF PAULI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRIGITTE MACK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HJALMAR HAGEDORN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BARBARA WOLLENBERG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: In some epithelial tumors, isoforms of CD44 are overexpressed and soluble isoforms detectable in serum samples are elevated. In squamous cell cancer of the head and neck (SCCHN) the alteration of CD44 isoforms could be associated with poor prognosis. A comprehensive study was undertaken to examine the value of CD44v6 as a tumor marker for SCCHN. Patients and Methods: Serum samples of SCCHN and healthy smokers were analyzed for soluble CD44v6 by ELISA. The expression of CD44 isoforms was determined by immunohistochemical staining of healthy and dysplastic tissue. Results: There was no significant difference between the serum levels of sCD44v6 in SCCHN and healthy smokers. Nor was there a correlation between the serum level of sCD44v6 and UICC stage, TNM stage or histological grading. In tissue of primary SCCHN, expression of CD44v6 was found as a strong, specific staining of the lower epithelial layers. Similar amounts of CD44v6-positive-labelled tumor cells were found in invasive carcinoma. Conclusion: Soluble CD44v6 is not a valuable tumor marker for SCCHN since the soluble form appears to be present in healthy smokers and does not reflect the stage of the disease.

  • CD44v6
  • neoplasm
  • squamous cell carcinoma of the head and neck
  • SCCHN
  • serum tumor marker
  • clinical prognostic factor

Footnotes

  • Received January 10, 2005.
  • Accepted April 21, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Soluble CD44v6 is Not a Sensitive Tumor Marker in Patients with Head and Neck Squamous Cell Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Soluble CD44v6 is Not a Sensitive Tumor Marker in Patients with Head and Neck Squamous Cell Cancer
MICHAELA ANDRATSCHKE, SARITA CHAUBAL, CHRISTOF PAULI, BRIGITTE MACK, HJALMAR HAGEDORN, BARBARA WOLLENBERG
Anticancer Research Jul 2005, 25 (4) 2821-2826;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Soluble CD44v6 is Not a Sensitive Tumor Marker in Patients with Head and Neck Squamous Cell Cancer
MICHAELA ANDRATSCHKE, SARITA CHAUBAL, CHRISTOF PAULI, BRIGITTE MACK, HJALMAR HAGEDORN, BARBARA WOLLENBERG
Anticancer Research Jul 2005, 25 (4) 2821-2826;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Anti-tumor Effect of Activated Canine B Cells With Interleukin-21 and Anti-B Cell Receptor
  • Claudin-10 in the Blood Brain Barrier Function of Cerebral Endothelial Cells and Transendothelial Invasion of Breast Cancer Cells
  • Development of Genetically Engineered Feeder Cells for Natural Killer Cell Expansion
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire